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We investigated the role of the apolipoprotein (Apo) E polymorphism in 
the prediction of CAD age of onset in a sample of unrelated living male 
(n = 65)  and female (n = 54) Caucasian subjects diagnosed with CAD. 
Cumulative distributions of age at the first diagnosis of CAD were 
estimated for each Apo E genotype and tested for homogeneity using the 
log-rank test. The Apo ~ 3 3  genotype was used as a reference group for all 
hypothesis tests. Analyses were performed separately in males and 
females. We found evidence suggesting that the presence of the Apo ~ 3 2  
genotype in males is associated with a significantly earlier CAD age of 
onset. These results suggest that the Apo E polymorphism may be a I gender-specific predictor of CAD age of onset. 
A central question of genetic studies of coronary 
artery disease (CAD) is whether knowledge about 
variation in the genome will be useful for the 
prediction of disease onset, rate of progression and 
severity (Sing et al. 1994). Traditional epidemiolog- 
ical studies of CAD have focused on identifying 
intermediate biochemical and physiological traits as 
well as environmental factors that may contribute 
to the prediction of presence of disease (Kame1 & 
Gordon 1970). Measured genotype information has 
the potential to contribute to our ability to predict 
CAD onset, rate of progression and severity because 
genotypes are typically not altered by the disease 
process or time, may represent information about 
a biochemical trait that cannot be measured, and 
may be easier and less expensive to obtain than 
biochemical and physiological information (Sing & 
Moll 1990b). 
Coronary artery disease is the result of progress- 
ive thickening of the arterial wall, due in part to 
lipid infiltration and smooth muscle cell prolifera- 
tion, presumably in response to injury to the endo- 
thelium. Of all the established risk factors for CAD, 
aging, as an index of changes in metabolism and 
the environment, is the strongest predictor of 
atherosclerotic plaque initiation and progression. 
Evidence that changes in lipid metabolism are in- 
dexed by aging (Hazard 1987, Kottke et al. 1991, 
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Kritchevsky 1980, Sing et al. 1979) suggests that 
this biochemical system may influence the onset 
of CAD. 
Genes that code for the important apolipoprotein 
components of plasma lipoproteins are considered 
to be candidates for determining interindividual 
differences in the risk of CAD (Sing & Moll 1990a). 
Of particular interest is the gene coding for apolipo- 
protein (Apo) E. The structure, function and meta- 
bolism of Apo E have been well characterized 
(Davignon 1993, Mahley 1988). Cross-sectional and 
longitudinal studies have demonstrated an associ- 
ation between allelic variation in the gene coding 
for Apo E and variation in risk of CAD (reviewed 
by Davignon 1993, StengPrd et al. 1995). These 
studies provide evidence suggesting that the Apo E 
gene may be a prototypical CAD susceptibility gene. 
In the present study, we investigated the role of 
the common Apo E genotypes in the prediction of 
CAD age of onset in living male and female subjects 
diagnosed with CAD. The cumulative distribution 
of age at first diagnosis of CAD was estimated for 
each Apo E genotype in males and females separ- 
ately. Homogeneity among genotypes was tested 
using the log-rank test. We found evidence sug- 
gesting the Apo ~ 3 2  genotype is associated with a 
significantly earlier CAD age of onset than the 
Apo ~ 3 3  genotype in males but not in females. 
22 
Apo E and CAD age of onset 
Material and methods 
Turner et al. (1989) provided details of the strategy 
used in the Rochester Family Heart Study (RFHS) 
to sample 276 multigenerational pedigrees repres- 
entative of the Caucasian population of Rochester, 
Minnesota, USA. A sample of 119 unrelated, living 
subjects diagnosed with CAD from these pedigrees 
were studied. This sample consisted of eight ~ 3 2  
females, seven ~ 3 2  males, 37 ~ 3 3  females, 34 ~ 3 3  
males, seven ~ 3 4  females, 21 ~ 3 4  males, two ~ 4 4  
females, and three ~44 males. Subjects with the ~ 4 4  
genotype were combined with the ~ 3 4  genotype for 
the statistical analyses reported here. Inferences 
were not altered when the ~ 4 4  genotype was 
removed from the analyses. 
All blood samples were collected in EDTA by 
venipuncture. Apo E isoforms were determined 
from frozen plasma samples by isoelectric focusing 
as described by Kamboh et al. (1988). Apo E 
genotypes were inferred from the Apo E isoform 
phenotypes. Each subject had a physical exam and 
a medical record evaluation at the time of 
enrollment into the RFHS. A clinical diagnosis of 
CAD was made if medical records indicated coron- 
ary surgery, myocardial infarction, definite angina, 
CAD, ischemic heart disease, or abnormal results 
from coronary angiography, an exercise multi-gated 
acquisition scanning, a treadmill exercise test, or an 
electrocardiogram. Age of onset of CAD was deter- 
mined from the age at first diagnosis of CAD. 
The goal of our statistical analysis was to deter- 
mine whether CAD age of onset distributions were 
homogeneous across the common Apo E genotypes. 
The most common Apo ~ 3 3  genotype was used as 
the reference group for contrasts with the ~ 3 2  and 
~ 3 4 + ~ 4 4  genotypes. All analyses were performed 
separately in males and females. The cumulative 
distribution of age at first diagnosis of CAD was 
estimated for each Apo E genotype. Homogeneity 
of the cumulative distributions across genotype 
strata was tested using the log-rank test ( Kalbfleisch 
& Prentice 1980). The log-rank test statistic is 
asymptotically distributed as a Chi-square distribu- 
tion with degrees of freedom equal to the number 
of strata tested minus one. The null hypothesis of 
no difference between cumulative distributions was 
rejected when p I 0.05. 
Results 
In both females and males, there were no statistic- 
ally significant differences in mean age at the time 
of enrollment into the RFHS ( ~ 3 3  females: 
71.4f8.6, ~ 3 2  females: 75.6k4.5, ~ 3 4 + s 4 4  females: 
71.1 f 10.4, ~ 3 3  males: 69.9 f8.8, ~ 3 2  males: 
62.6k 14.6, ~ 3 4 + ~ 4 4  males: 67.5f 11.0). In a pair- 
wise comparison with the Apo ~ 3 3  genotype, no 
statistically significant difference in mean age of 
onset of CAD was detected between ~ 3 3  females 
(65.4 k 10.3 years) and ~ 3 2  females ( 70.4 & 7.3 years) 
or ~ 3 4 +  ~ 4 4  females (67.7 f 10.1 years). No statistic- 
ally significant difference in mean age of onset was 
detected between ~ 3 4  + ~ 4 4  males (59.5 f 1 1.2 years) 
and ~ 3 3  males (61.7+ 10.9). However, there was a 
statistically significant difference in mean age of 
onset between ~ 3 2  males (52.1 k 14.0 years) and ~ 3 3  
males (61.7 f 10.9 years). 
The proportion of subjects with a first diagnosis 
of CAD by a particular age is summarized in Fig. 1 
for each of the Apo E genotype and gender strata. 
The log-rank test of homogeneity indicates that 
male subjects with the Apo ~ 3 2  genotype had a 
statistically significant different cumulative distribu- 
tion than subjects with the ~ 3 3  genotype (Fig. 1A). 
This observation is consistent with the statistically 
significant difference in the mean age of onset 
between these two groups. No other contrast 
between subjects with the ~ 3 2  or ~ 3 4 +  €44 genotypes 
and subjects with the ~ 3 3  genotype (Fig. 1B-1D) 
was significant at the 0.05 level of probability in 
either gender. 
Discussion 
Evidence from studies of coronary arteries in chil- 
dren and young adults suggest that atherosclerotic 
plaques begin to develop in children 10- 15 years of 
age in approximately half of the population (Stary 
1987). An important public health problem is to 
identify risk factors that predict an early CAD age 
of onset, with the ultimate goal of improving disease 
prevention. A fundamental question facing geneti- 
cists is whether information about the genome will 
be useful for predicting the onset, progression and 
seventy of common chronic diseases like CAD (Sing 
et al. 1994). The results presented in this study 
suggest that variation in the Apo E gene may play 
a gender-specific role in the prediction of CAD age 
of onset. Because several of the gender and genotype 
strata had small sample sizes, this conclusion must 
remain a working hypothesis to be confirmed or 
refuted in subsequent studies. 
Our finding that the Apo ~ 3 2  genotype is predict- 
ive of an earlier age of onset in males is consistent 
with two earlier reports of an association between 
the EZ allele and risk of CAD (de Andrade et al. 
1995, Eto et al. 1989). This finding is, however, 
inconsistent with the general conclusion that has 
been drawn from previous studies investigating the 
association between Apo E genotype and risk of 
CAD (reviewed by Davignon 1993). In most stud- 
ies, the frequency of the s4 allele was significantly 
higher in patients with confirmed CAD than in 
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Fig. 1. Cumulative distributions summarizing the proportion of subjects with onset of CAD by a particular age. A, Distributions 
for €32 and ~ 3 3  males. B, Distributions for ~ 3 2  and ~ 3 3  females. C, Distributions for ~ 3 3  and ~ 3 4 f ~ 4 4  males. D. Distributions for 
€33 and ~ 3 4 + ~ 4 4  females. 
healthy controls or in random population samples. 
A recent prospective study following two cohorts 
of elderly men concluded that the ~4 allele was a 
significant predictor of future CAD mortality in 
two Finnish populations (StengArd et al. 1995). 
Also, the ~4 allele has been associated with an 
earlier age of myocardial infarction (Cumming & 
Robertson 1984, Lenzen et al. 1986). Differences in 
disease classification, sampling design, the popula- 
tion of inference and/or the small sample size of 
the present study may explain inconsistent findings. 
It is possible that effects of one or more of the 
genotypes of the many susceptibility genes which 
influence CAD age of onset interact with Apo E 
effects in such a way that particular Apo E genotypes 
appear to have different marginal effects on risk of 
CAD in different contexts. 
What role might the Apo ~2 allele play in suscepti- 
bility to an earlier age of onset of CAD? There is 
accumulating evidence suggesting that the Apo ~2 
allele has atherogenic potential. The Apo ~2 allele 
may be associated with increased levels of triglycer- 
ide-rich lipoproteins which are believed to play a 
role in the development of atherosclerosis 
(Davignon 1993). A study by Reilly et al. (1991) 
in the same Rochester, MN population observed 
higher mean levels of triglycerides in ~ 3 2  males than 
~ 3 3  males. Thus, the association between the 
Apo ~ 3 2  genotype and an earlier age of onset of 
CAD in males from the present study could be 
partly due to the influence of the ~2 allele on plasma 
triglyceride levels. This hypothesis is supported in 
part by a study of 5919 middle-aged men that found 
plasma triglyceride levels were a significant pre- 
dictor of early onset CAD (Benfante et al. 1989). 
Studies of the relationship between plasma triglycer- 
ide levels and age of onset in different Apo E 
genotypes are needed to fully investigate this 
hypothesis. 
The general utility of genomic information for 
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predicting common chronic disease onset, progres- 
sion and severity is yet to be evaluated for the large 
number of candidate susceptibility genes that have 
been described. Gene by gene and gene by environ- 
ment interactions are expected to influence how 
genomic information might improve prediction. The 
gender- and genotype-specific findings in this study 
add support to the hypothesis that the predictive 
value of a fraction of the genome type information 
is context dependent (Sing et al. 1996). 
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